American Society of Hirudotherapy

Novel Leech Antimicrobial Peptides, Hirunipins: Real-Time 3D Monitoring of Antimicrobial and Antibiofilm Mechanisms Using Optical Diffraction Tomography

Research article published in Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: In vitro / laboratorySafety & Infection ControlClinical LiteratureKumar SD et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025

Abstract

Antimicrobial peptides (AMPs) are promising agents for treating antibiotic-resistant bacterial infections. Although discovering novel AMPs is crucial for combating multidrug-resistant bacteria and biofilm-related infections, their clinical potential relies on precise, real-time evaluation of efficacy, toxicity, and mechanisms. Optical diffraction tomography (ODT), a label-free imaging technology, enables real-time visualization of bacterial morphological changes, membrane damage, and biofilm formation over time. Here, a computational analysis of the leech transcriptome using an advanced AI-based peptide screening strategy with ODT to identify potential AMPs is employed. Among the 19 potential AMPs identified, hirunipin 2 demonstrates potent antibacterial activity, low mammalian cytotoxicity, and minimal hemolytic effects. It demonstrates efficacy comparable to melittin, resistance to physiological salts and human serum, and a low likelihood of inducing bacterial resistance. Microscopy and 3D-ODT confirm its disruption of bacterial membranes and intracellular aggregation, leading to cell death. Notably, hirunipin 2 effectively inhibits biofilm formation, eradicates preformed biofilms, and synergizes with antibiotics against multidrug-resistant Acinetobacter baumannii (MDRAB) by enhancing membrane permeability. Additionally, hirunipin 2 significantly suppresses pro-inflammatory cytokine expression in LPS-stimulated macrophages, highlighting its anti-inflammatory properties. These findings highlight hirunipin 2 as a strong candidate for developing novel antibacterial, anti-inflammatory, and antibiofilm therapies, particularly against multidrug-resistant bacterial infections.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAntimicrobial PeptidesAnti-Bacterial AgentsBiofilmsLeechesMicrobial Sensitivity TestsTomography, OpticalAnimalsComputer SimulationTranscriptomeRAW 264.7 CellsNIH 3T3 CellsHaCaT CellsHumansMice

Summary

Screening the leech transcriptome with AI and optical diffraction tomography yielded 19 candidate antimicrobial peptides; hirunipin 2 showed potent antibacterial and antibiofilm activity, including synergy with antibiotics against multidrug-resistant Acinetobacter baumannii, with low mammalian cytotoxicity.

Why This Matters for Hirudotherapy

Using AI-based screening of the leech transcriptome combined with label-free optical diffraction tomography, this study identified 19 candidate antimicrobial peptides and characterized hirunipin 2, which showed potent antibacterial activity comparable to melittin, low mammalian cytotoxicity and hemolysis, disruption of bacterial membranes, inhibition and eradication of biofilms, synergy with antibiotics against multidrug-resistant Acinetobacter baumannii, and suppression of pro-inflammatory cytokines in stimulated macrophages. This directly advances the medicinal-leech secretome drug-discovery story by extending leech-derived bioactives beyond anticoagulation into a new class of antimicrobial and anti-biofilm agents, mechanistically plausible support for the long-observed low infection rates around leech feeding. The important caveat is that these are preclinical, in vitro and cell-based findings (bacterial cultures, biofilm models, and macrophage and other cell lines); hirunipin 2 is a discovery-stage candidate with no animal efficacy or human data reported here, so it does not establish clinical benefit and must not be presented as an approved or proven therapy.

Citation

Reference (Vancouver style)

Kumar SD, Park J, Radhakrishnan NK, Aryal YP, Jeong GH, Pyo IH, et al. Novel Leech Antimicrobial Peptides, Hirunipins: Real-Time 3D Monitoring of Antimicrobial and Antibiofilm Mechanisms Using Optical Diffraction Tomography. Adv Sci (Weinh). 2025;12(10):e2409803. doi:10.1002/advs.202409803. PMID: 39792785

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.